Q4 EPS Estimates for Globus Medical Reduced by Roth Capital

Globus Medical, Inc. (NYSE:GMED) – Investment analysts at Roth Capital decreased their Q4 2025 earnings per share (EPS) estimates for Globus Medical in a report issued on Wednesday, November 6th. Roth Capital analyst J. Wittes now anticipates that the medical device company will earn $0.91 per share for the quarter, down from their prior forecast of $0.92. The consensus estimate for Globus Medical’s current full-year earnings is $2.84 per share.

Several other brokerages have also recently issued reports on GMED. Bank of America boosted their price objective on Globus Medical from $55.00 to $80.00 and gave the company an “underperform” rating in a report on Wednesday. Truist Financial upped their price objective on Globus Medical from $78.00 to $79.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Stifel Nicolaus boosted their target price on shares of Globus Medical from $80.00 to $92.00 and gave the company a “buy” rating in a research note on Wednesday. Barclays increased their price target on shares of Globus Medical from $85.00 to $93.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Finally, Piper Sandler lifted their price objective on shares of Globus Medical from $80.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Globus Medical currently has an average rating of “Moderate Buy” and an average price target of $87.09.

Globus Medical Price Performance

NYSE GMED opened at $80.86 on Thursday. Globus Medical has a 1 year low of $43.38 and a 1 year high of $84.87. The company has a market capitalization of $10.95 billion, a PE ratio of 269.53, a P/E/G ratio of 2.06 and a beta of 1.17. The company has a fifty day moving average of $72.28 and a 200 day moving average of $68.46.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.65 by $0.18. The business had revenue of $625.71 million for the quarter, compared to the consensus estimate of $604.69 million. Globus Medical had a net margin of 1.82% and a return on equity of 8.70%. The business’s revenue for the quarter was up 63.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.57 EPS.

Institutional Investors Weigh In On Globus Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in GMED. Select Equity Group L.P. acquired a new stake in shares of Globus Medical in the second quarter valued at about $91,711,000. Millennium Management LLC lifted its stake in Globus Medical by 1,171.5% in the 2nd quarter. Millennium Management LLC now owns 1,363,834 shares of the medical device company’s stock worth $93,409,000 after purchasing an additional 1,256,570 shares in the last quarter. Magnetar Financial LLC boosted its holdings in shares of Globus Medical by 198.6% during the 1st quarter. Magnetar Financial LLC now owns 1,689,287 shares of the medical device company’s stock worth $90,613,000 after purchasing an additional 1,123,540 shares during the last quarter. Motley Fool Asset Management LLC grew its position in shares of Globus Medical by 1,263.7% in the first quarter. Motley Fool Asset Management LLC now owns 848,164 shares of the medical device company’s stock valued at $45,496,000 after purchasing an additional 785,970 shares in the last quarter. Finally, Burgundy Asset Management Ltd. increased its holdings in shares of Globus Medical by 46.1% in the first quarter. Burgundy Asset Management Ltd. now owns 2,479,837 shares of the medical device company’s stock valued at $133,018,000 after purchasing an additional 782,285 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Insider Transactions at Globus Medical

In related news, SVP Kelly Huller sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $81.01, for a total value of $405,050.00. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Daniel T. Scavilla sold 60,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $80.02, for a total value of $4,801,200.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Kelly Huller sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $81.01, for a total value of $405,050.00. The disclosure for this sale can be found here. Insiders sold 110,000 shares of company stock valued at $8,512,850 over the last 90 days. Corporate insiders own 18.54% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.